MSMałgorzata Szkutnik

Małgorzata Szkutnik

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Małgorzata Szkutnik has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Jacek Białkowski

    Department of Pediatric Cardiology and Congenital Heart Defects, Medical University of Silesia, Silesian Center for Heart Diseases, Zabrze, Poland

    53 shared publications
  • Roland Fiszer

    Department of Pediatric Cardiology and Congenital Heart Defects, Silesian Center for Heart Diseases in Zabrze; Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

    34 shared publications
  • Jacek Kusa

    9 shared publications
  • Michal Galeczka

    Medical University of Silesia in Katowice, Silesian Center for Heart Diseases

    9 shared publications
  • Beata Chodór

    Department of Congenital Heart Diseases and Paediatric Cardiology, Silesian Centre for Heart Diseases

    7 shared publications
  • Mateusz Knop

    Department of Pediatric Cardiology and Congenital Heart Defects, Silesian Center for Heart Diseases in Zabrze; Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland

    6 shared publications

Latest Publications

  • Medium- and long-term follow-up of transcatheter closure of ruptured sinus of Valsalva aneurysm in Central Europe population

    by Michal Galeczka, Jan Glowacki, Nataliia Yashchuk, Igor Ditkivskyy, Dominika Rojczyk, Mateusz Knop, Sebastian Smerdzinski, Bogdan Cherpak, Malgorzata Szkutnik, Jacek Bialkowski, et al.


  • Long-term effects of combined percutaneous atrial septal defect occlusion and pulmonary valvuloplasty in children < 2.5 years old

    by Sebastian Smerdziński, Jacek Białkowski, Małgorzata Szkutnik, Mateusz Knop, Michał Gałeczka, Roland Fiszer


  • Open Access

    Successful atrial septal defect transcatheter closure in a patient with pentalogy of Cantrell and ectopia cordis

    by Michal Galeczka, Roland Fiszer, Mateusz T. Knop, Sebastian Smerdzinski, Malgorzata Szkutnik, Jacek Bialkowski


  • Transcatheter closure of atrial septal defects type 2 in children under three years of age

    by Mateusz T. Knop, Jacek Białkowski, Małgorzata Szkutnik, Roland Fiszer, Sebastian Smerdziński, Michał Gałeczka, Linda Litwin

    Background: Atrial septal defect type II (ASD), according to current standards, is closed percutaneously usually after the child has reached the age of 4-5 years. There are limited data regarding such treatment in smaller infants. Aims: To evaluate feasibility, safety and efficacy of percutaneous ASD closure in children under 3 years of age. Methods: Overall group of 149 children < 3 years with hemodynamically significant ASD, who underwent effective transcatheter ASD closure in one tertiary center between 1999 and 2014 were included. Mean procedural age of treated children was 2,2 years and weight 12,5 kg. In all nitinol wire mesh devices were applied (mostly Amplatzer Septal Occluders). ASD was closed by standard technique (except few cases when left disc of implant was inserted initially into right pulmonary vein to prevent oblique position of the device). Complications related to the procedure were divided into major and minor ones. Results: There were 97 children with a single ASD and 52 with double/multiple ASD. No death, no implant embolization, and one major complications occurred during procedure and in follow-up. ASD was completely closed in all but 8 patients with double/multiple ASD. Right ventricle diameter normalization occurred in all during 1 year follow-up. In majority of the patients in follow-up an acceleration of physical development and resolution of accompanying morbidity was observed. Conclusions: Percutaneous ASD device closure can be performer safely in children below 3 years of age with low risk of complication during and after the procedure. Background: Atrial septal defect type II (ASD), according to current standards, is closed percutaneously usually after the child has reached the age of 4-5 years. There are limited data regarding such treatment in smaller infants. Aims: To evaluate feasibility, safety and efficacy of percutaneous ASD closure in children under 3 years of age. Methods: Overall group of 149 children < 3 years with hemodynamically significant ASD, who underwent effective transcatheter ASD closure in one tertiary center between 1999 and 2014 were included. Mean procedural age of treated children was 2,2 years and weight 12,5 kg. In all nitinol wire mesh devices were applied (mostly Amplatzer Septal Occluders). ASD was closed by standard technique (except few cases when left disc of implant was inserted initially into right pulmonary vein to prevent oblique position of the device). Complications related to the procedure were divided into major and minor ones. Results: There were 97 children with a single ASD and 52 with double/multiple ASD. No death, no implant embolization, and one major complications occurred during procedure and in follow-up. ASD was completely closed in all but 8 patients with double/multiple ASD. Right ventricle diameter normalization occurred in all during 1 year follow-up. In majority of the patients in follow-up an acceleration of physical development and resolution of accompanying morbidity was observed. Conclusions: Percutaneous ASD device closure can be performer safely in children below 3 years of age with low risk of complication during and after the procedure.


  • Open Access

    Immediate and long-term outcomes of percutaneous transcatheter pulmonary valve implantation

    by Roland Fiszer, Paweł Dryżek, Małgorzata Szkutnik, Sebastian Góreczny, Alexandra Krawczuk, Jadwiga Moll, Tomasz Moszura, Szymon Pawlak, Jacek Białkowski

    Background: Transcutaneous pulmonary valve replacement (TPVR) has become an alternative to heart surgery for patients after previous right ventricular outflow tract (RVOT) or pulmonary artery (PA) surgical interventions. The objective was to present immediate and long-term outcomes of transcutaneous pulmonary valve replacement. Methods: Between 06/2009 and 06/2016, 46 patients underwent TPVR. Initial diagnoses included tetralogy of Fallot, common arterial trunk, transposition of great arteries post Rastelli correction, left ventricle outflow obstruction after Ross operation, pulmonary atresia, and isolated dysplastic pulmonary valve stenosis. Thirty eight patients (78%) had previously implanted conduits in the pulmonary position, the rest had either RVOT patch reconstruction (n = 6; 13%) or biological valve implantation (n = 2; 4%). They presented primarily with pulmonary stenosis (n = 18; 39%) or regurgitation (n = 28; 60%). Results: All procedures were successful — 44 Melody and 2 Edwards-Sapien valves were implanted. Before each procedure exclusion of potential coronary compression and RVOT prestenting was performed. Significant RVOT systolic gradient reduction (from 35.3 ± 19.5 to 13.5 ± 7.1 mm Hg; p < 0.001) and decrease of right to left ventricle systolic pressure ratio from 0.58 ± 0.18 to mean 0.37 ± 0.1 (p < 0.001) was achieved. Also, in every patient PA-RVOT competence was restored, with minor incompetence in only a few patients. Post procedure follow-up ranged from 2 to 86 (mean 35.2) months. Follow-up fluoroscopy or chest X-ray revealed 6 stent fractures (2 stent defragmentation - with only one significant valve stenosis). Conclusions: TPVR is a safe procedure with encouraging results, it also enables deferring surgical reintervention in the majority of patients. Background: Transcutaneous pulmonary valve replacement (TPVR) has become an alternative to heart surgery for patients after previous right ventricular outflow tract (RVOT) or pulmonary artery (PA) surgical interventions. The objective was to present immediate and long-term outcomes of transcutaneous pulmonary valve replacement. Methods: Between 06/2009 and 06/2016, 46 patients underwent TPVR. Initial diagnoses included tetralogy of Fallot, common arterial trunk, transposition of great arteries post Rastelli correction, left ventricle outflow obstruction after Ross operation, pulmonary atresia, and isolated dysplastic pulmonary valve stenosis. Thirty eight patients (78%) had previously implanted conduits in the pulmonary position, the rest had either RVOT patch reconstruction (n = 6; 13%) or biological valve implantation (n = 2; 4%). They presented primarily with pulmonary stenosis (n = 18; 39%) or regurgitation (n = 28; 60%). Results: All procedures were successful — 44 Melody and 2 Edwards-Sapien valves were implanted. Before each procedure exclusion of potential coronary compression and RVOT prestenting was performed. Significant RVOT systolic gradient reduction (from 35.3 ± 19.5 to 13.5 ± 7.1 mm Hg; p < 0.001) and decrease of right to left ventricle systolic pressure ratio from 0.58 ± 0.18 to mean 0.37 ± 0.1 (p < 0.001) was achieved. Also, in every patient PA-RVOT competence was restored, with minor incompetence in only a few patients. Post procedure follow-up ranged from 2 to 86 (mean 35.2) months. Follow-up fluoroscopy or chest X-ray revealed 6 stent fractures (2 stent defragmentation - with only one significant valve stenosis). Conclusions: TPVR is a safe procedure with encouraging results, it also enables deferring surgical reintervention in the majority of patients.


  • Implantation of stents for postsurgical recoarctation of the aorta in adolescents and adults

    by Sylwia Sulik-Gajda, Roland Fiszer, Jacek Białkowski, Beata Chodór, Szymon Pawlak, Małgorzata Szkutnik

    Background: Results of stent implantation (SI) of postsurgical recoarctation of the aorta (ReCoA) are not frequently published. Aim: This study sought to retrospectively evaluate results of SI in ReCoA in older children and adults. Methods: Twenty-eight SI were performed on 26 ReCoA patients with a median age of 23(10-65) years. Dependent upon availability, the following stents were applied -Palmaz, Cheatham Platinum (CP), Andrastents XL/XXL(AS), Covered CP (CVCP) stents and selfexpanding stents (Smart). Generally high pressure balloons were applied to dilate stents. Results: The procedure was effective in 20/26 patients (77,7%). The mean peak systolic gradient reduced from 40,5+/- 18,7 mmHg to 13,1+/- 12,1 mm Hg (pConclusions: Endovascular stenting of recoarctation of the aorta in adults and adolescents appears to be an acceptable method of treatment in experienced hands. However, for some patients the presence of a stiff lesion can provoke suboptimal results. Considering the serious complications which may occur after SI, following surgery all patients should have regular follow up (including an imaging study). Covered stents should always be available in the cathlab as a rescue device when implanting stents in CoA patients. Background: Results of stent implantation (SI) of postsurgical recoarctation of the aorta (ReCoA) are not frequently published. Aim: This study sought to retrospectively evaluate results of SI in ReCoA in older children and adults. Methods: Twenty-eight SI were performed on 26 ReCoA patients with a median age of 23(10-65) years. Dependent upon availability, the following stents were applied -Palmaz, Cheatham Platinum (CP), Andrastents XL/XXL(AS), Covered CP (CVCP) stents and selfexpanding stents (Smart). Generally high pressure balloons were applied to dilate stents. Results: The procedure was effective in 20/26 patients (77,7%). The mean peak systolic gradient reduced from 40,5+/- 18,7 mmHg to 13,1+/- 12,1 mm Hg (pConclusions: Endovascular stenting of recoarctation of the aorta in adults and adolescents appears to be an acceptable method of treatment in experienced hands. However, for some patients the presence of a stiff lesion can provoke suboptimal results. Considering the serious complications which may occur after SI, following surgery all patients should have regular follow up (including an imaging study). Covered stents should always be available in the cathlab as a rescue device when implanting stents in CoA patients.


  • Difficult diagnosis of Kawasaki disease in a patient with giant coronary artery aneurysms

    by Michał Gałeczka, Roland Fiszer, Blandyna Karwot, Jan Głowacki, Małgorzata Szkutnik


  • Immediate and long term outcomes of native aortic coarctation and postsurgical aortic recoarctation treated with stent implantation: one Center experience

    by Sylwia Sulik, Roland Fiszer, Giancarla Scalone, Omar Gomez Monterrosas, Jacek Białkowski, Małgorzata Szkutnik

    INTRODUCTION Stent implantation has become the treatment of choice for native aortic coarctation (CoA) and postsurgical aortic recoarctation (reCoA) in adults and adolescents. OBJECTIVES This study aimed to compare the immediate and long‑term outcomes of patients with native CoA and postsurgical reCoA who underwent stent implantation in our center. PATIENTS AND METHODS The data of 136 patients with native CoA and reCoA who underwent stent implantation between May 1999 and December 2016 were retrospectively analyzed. The study population was divided into 2 groups: 108 patients with native CoA and 28 patients with reCoA. Clinical and procedural characteristics and immediate and long‑term outcomes after the intervention were compared between the groups. The use of antihypertensive drugs was analyzed in all patients. RESULTS There were no significant differences in the clinical characteristics of the study groups. The gradient before the intervention was significantly higher in the native CoA than in the reCoA group (P = 0.011), and the diameter of stenosis before the intervention was smaller in the native CoA group compared with the ReCoA group (P = 0.003). Procedural treatment was successful in 77.8% of the patients with native CoA and 78.5% of those with reCoA. There were no differences in the immediate and long‑term outcomes between the groups. The antihypertensive treatment was tapered or discontinued in about 34% of the study population. CONCLUSIONS Stenting is an effective and safe procedure in patients with native CoA and reCoA, with good late outcomes.